Depression increases the risk of diabetes mellitus type 2 development and the subsequent risks of hyperglycemia, insulin resistance, micro- and macro-vascular complications. The association between depression and diabetes mellitus type 2 may include autonomic and neurohormonal dysregulation, weight gain, inflammation, and structural changes in the hippocampus.
Objective of the work. To evaluate the psychological status and quality of life indicators in patients with diabetes mellitus type 2 and chronic gastritis before and after the treatment with the use of medicine Magnicum-Antistress.
Materials and methods. Based on the Endocrinology Department of the Transcarpathia Regional Clinical hospital named after A.Novak there were examined 40 patients, whose average age was to 53.7±4.1 years. All patients with diabetes mellitus type 2 and chronic gastritis were assessed for quality of life, psychological status, and stress levels using questionnaires, namely using the SF-36, “PSM-25 Psychological Stress Scale methodology”, Holmes and Rahe stress test. After the survey, all patients were treated with Magnicum-Antistress medicine on the background of pathogenetic treatment.
Results. Thus, after the course of treatment during 1 month, the level of stress decreased, so in the male patients the high level of stress was observed in 58.3% of patients, and among female patients – 35.8%. Also, the level of stress-resistance increased, so in male patients, the low stress-resistance level was observed in 66.7% of patients, and among female patients – 25%. After the course of treatment according to the Quality of Life Assessment Scale (SF-36), patients showed a positive tendency in the indicators of the psychological and physical health components.
Conclusions. The level of chronic stress in patients with DM type 2 and CG is mostly high (52.5%). The level of stress-resistance in the vast majority of patients with DM type 2 and CG is low (52.5%). Complex therapy with the use of the medicine Magnicum-Antistress in patients with DM type 2 and CG is pathogenetically justified, and also leads to an improvement in the quality of life and stress-resistance in these patients.
Semenkovich K, et al. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs. 2015; 75(6): 577-587. DOI: https://doi.org/10.1007/s40265-015-0347-4 [PMid:25851098]
Tarleton EK, et al. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. PLoS One. 2017; 12(6): e0180067. DOI: https://doi.org/10.1371/journal.pone.0180067 [PMid:28654669 PMCid:PMC5487054]
Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015; 7(9): 8199-8226. DOI: https://doi.org/10.3390/nu7095388 [PMid:26404370 PMCid:PMC4586582]
Serefko A, Szopa A, Poleszak E. Magnesium and depression. Magnesium research. 2016; 29(3): 112-119.
Barbagallo M, Dominguez LJ. Magnesium and type 2 diabetes. World journal of diabetes. 2015; 6(10): 1152. DOI: https://doi.org/10.4239/wjd.v6.i10.1152 [PMid:26322160 PMCid:PMC4549665]
Ramadass S, Basu S, Srinivasan AR. Serum magnesium levels as an indicator of status of Diabetes Mellitus type 2. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015; 9(1): 42-45. https://doi.org/10.1016/j.dsx.2014.04.024 DOI: https://doi.org/10.1016/j.dsx.2014.04.024 [PMid:25470649]
Palmer BF, Clegg DJ. Electrolyte and acid-base disturbances in patients with diabetes mellitus. New England Journal of Medicine. 2015; 373(6): 548-559. DOI: https://doi.org/10.1056/NEJMra1503102 [PMid:26244308]
Rodríguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial. Archives of Medical Research. 2014; 45(5): 388-393. DOI: https://doi.org/10.1016/j.arcmed.2014.05.003 [PMid:24830937]
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.